Back to search

Article

Scalable Markers for Early Cognitive Decline: Plasma p-tau217, Subjective Cognitive Concerns, and Digital Testing: Results from the A4/LEARN studies

2025-10-15

Abstract excerpt

<h4>Background and Objectives</h4> Although amyloid positron emission tomography (PET) and Cerebrospinal fluid (CSF) biomarkers remain the standard for confirming Alzheimer’s disease (AD) pathology, their use is impractical for screening or routine prognostic assessment. Plasma phosphorylated tau 217 (p-tau217), subjective cognitive concerns, and computerized cognitive testing are non-invasive, scalable, and feas...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
427cb8de-7373-5f1c-a846-cbb261818f23
DOI
10.1101/2025.10.14.25338009
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Scalable Markers for Early Cognitive Decline: Plasma p-tau217, Subjective Cognitive Concerns, and Digital Testing: Results from the A4/LEARN studiesDOI 10.1101/2025.10.14.25338009
Prediction of future Alzheimer’s disease dementia using plasma phospho-tau combined with other accessible measuresSemantic proximity
Plasma p-tau217, p-tau181, and Aβ42 Predicts Amyloid PET Positivity in Cognitively Unimpaired AdultsSemantic proximity
Plasma p-tau217 predicts cognitive impairments up to ten years before onset in normal older adultsSemantic proximity
Clinical application of plasma P-tau217 to assess eligibility for amyloid-lowering immunotherapy in memory clinic patients with early Alzheimer’s diseaseSemantic proximity
Promising clinical tools for specific Alzheimer disease diagnosis from plasma pTau217 and ApoE genotype in a cognitive disorder unitSemantic proximity
Plasma biomarkers predict amyloid conversion and cognitive decline in cognitively unimpaired adultsSemantic proximity
Association of Plasma Phosphorylated Tau 217 With Clinical Deterioration Across Alzheimer Disease StagesSemantic proximity
Concurrent Detection of Cognitive Impairment and Amyloid Positivity with a Next-Generation Digital Cognitive AssessmentSemantic proximity
Plasma biomarker levels and cognitive decline in a heterogenous community-based cohort with multiple comorbiditiesSemantic proximity
Robustness of plasma p-Tau217 diagnostic thresholds for Alzheimer’s disease across various clinical populations and laboratory environmentsSemantic proximity
Predicting Preclinical Cognitive Decline Using Plasma P-tau217 and <i>APOE</i> Genotype in 8,582 Individuals From Different Ethnic GroupsSemantic proximity
Validation of the self-test computerised PROTECT Cognitive Test System for detection of dementia and Mild Cognitive ImpairmentSemantic proximity
Select a neighboring publication to make it the new centre.